nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—Reflexes abnormal—Hydrochlorothiazide—nephrolithiasis	0.0441	0.102	CcSEcCtD
Bortezomib—Anxiety disorder—Hydrochlorothiazide—nephrolithiasis	0.0237	0.0549	CcSEcCtD
Bortezomib—PSMD2—Hydroflumethiazide—Hydrochlorothiazide—nephrolithiasis	0.0177	1	CbGdCrCtD
Bortezomib—Hair disorder—Hydrochlorothiazide—nephrolithiasis	0.0162	0.0374	CcSEcCtD
Bortezomib—Oral disorder—Hydrochlorothiazide—nephrolithiasis	0.0145	0.0336	CcSEcCtD
Bortezomib—Cutaneous vasculitis—Hydrochlorothiazide—nephrolithiasis	0.0141	0.0325	CcSEcCtD
Bortezomib—PSMA1—renal system—nephrolithiasis	0.0137	0.0529	CbGeAlD
Bortezomib—Abnormal faeces—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0297	CcSEcCtD
Bortezomib—PSMD1—nephron tubule—nephrolithiasis	0.0127	0.0489	CbGeAlD
Bortezomib—CYP2C19—urine—nephrolithiasis	0.0114	0.044	CbGeAlD
Bortezomib—PSMD2—nephron tubule—nephrolithiasis	0.0112	0.0433	CbGeAlD
Bortezomib—PSMD1—cortex of kidney—nephrolithiasis	0.0109	0.0418	CbGeAlD
Bortezomib—Atrioventricular block complete—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0243	CcSEcCtD
Bortezomib—PSMD2—renal system—nephrolithiasis	0.0102	0.0394	CbGeAlD
Bortezomib—SLC31A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00988	0.0341	CbGpPWpGaD
Bortezomib—PSMD2—kidney—nephrolithiasis	0.00988	0.0381	CbGeAlD
Bortezomib—PSMB5—nephron tubule—nephrolithiasis	0.00987	0.038	CbGeAlD
Bortezomib—PSMD2—cortex of kidney—nephrolithiasis	0.00962	0.0371	CbGeAlD
Bortezomib—PSMB8—cortex of kidney—nephrolithiasis	0.00956	0.0368	CbGeAlD
Bortezomib—CYP1A2—urine—nephrolithiasis	0.00932	0.0359	CbGeAlD
Bortezomib—SLC31A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00919	0.0317	CbGpPWpGaD
Bortezomib—CYP2C9—urine—nephrolithiasis	0.00885	0.0341	CbGeAlD
Bortezomib—Electrolyte imbalance—Hydrochlorothiazide—nephrolithiasis	0.00879	0.0203	CcSEcCtD
Bortezomib—PSMB1—nephron tubule—nephrolithiasis	0.00862	0.0332	CbGeAlD
Bortezomib—PSMB5—cortex of kidney—nephrolithiasis	0.00845	0.0325	CbGeAlD
Bortezomib—PSMB2—nephron tubule—nephrolithiasis	0.00842	0.0324	CbGeAlD
Bortezomib—PSMA1—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.008	0.0276	CbGpPWpGaD
Bortezomib—PSMD1—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.00797	0.0275	CbGpPWpGaD
Bortezomib—PSMD2—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.00793	0.0273	CbGpPWpGaD
Bortezomib—PSMB1—renal system—nephrolithiasis	0.00784	0.0302	CbGeAlD
Bortezomib—PSMB2—renal system—nephrolithiasis	0.00765	0.0295	CbGeAlD
Bortezomib—PSMB1—kidney—nephrolithiasis	0.00758	0.0292	CbGeAlD
Bortezomib—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.00749	0.0173	CcSEcCtD
Bortezomib—PSMB2—kidney—nephrolithiasis	0.0074	0.0285	CbGeAlD
Bortezomib—PSMB1—cortex of kidney—nephrolithiasis	0.00738	0.0284	CbGeAlD
Bortezomib—SLC31A1—nephron tubule—nephrolithiasis	0.00729	0.0281	CbGeAlD
Bortezomib—PSMB2—cortex of kidney—nephrolithiasis	0.0072	0.0277	CbGeAlD
Bortezomib—PSMA1—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00714	0.0246	CbGpPWpGaD
Bortezomib—PSMD1—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00711	0.0245	CbGpPWpGaD
Bortezomib—PSMD2—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00707	0.0244	CbGpPWpGaD
Bortezomib—CYP3A4—urine—nephrolithiasis	0.00675	0.026	CbGeAlD
Bortezomib—CYP2D6—urine—nephrolithiasis	0.00664	0.0256	CbGeAlD
Bortezomib—SLC31A1—renal system—nephrolithiasis	0.00662	0.0255	CbGeAlD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00648	0.0223	CbGpPWpGaD
Bortezomib—SLC31A1—kidney—nephrolithiasis	0.0064	0.0247	CbGeAlD
Bortezomib—SLC31A1—cortex of kidney—nephrolithiasis	0.00624	0.024	CbGeAlD
Bortezomib—PSMB2—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.00607	0.0209	CbGpPWpGaD
Bortezomib—PSMB5—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.00607	0.0209	CbGpPWpGaD
Bortezomib—PSMB1—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.00607	0.0209	CbGpPWpGaD
Bortezomib—PSMB8—Hedgehog 'off' state—ADCY10—nephrolithiasis	0.00598	0.0206	CbGpPWpGaD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00593	0.0204	CbGpPWpGaD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00593	0.0204	CbGpPWpGaD
Bortezomib—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.00578	0.0134	CcSEcCtD
Bortezomib—Encephalopathy—Hydrochlorothiazide—nephrolithiasis	0.00572	0.0132	CcSEcCtD
Bortezomib—PSMB2—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00541	0.0187	CbGpPWpGaD
Bortezomib—PSMB1—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00541	0.0187	CbGpPWpGaD
Bortezomib—PSMB5—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00541	0.0187	CbGpPWpGaD
Bortezomib—PSMB8—Signaling by Hedgehog—ADCY10—nephrolithiasis	0.00534	0.0184	CbGpPWpGaD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00449	0.0155	CbGpPWpGaD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00449	0.0155	CbGpPWpGaD
Bortezomib—Numbness—Hydrochlorothiazide—nephrolithiasis	0.00443	0.0102	CcSEcCtD
Bortezomib—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.00424	0.0098	CcSEcCtD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00418	0.0144	CbGpPWpGaD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00418	0.0144	CbGpPWpGaD
Bortezomib—Rhabdomyolysis—Hydrochlorothiazide—nephrolithiasis	0.00415	0.00959	CcSEcCtD
Bortezomib—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00406	0.0094	CcSEcCtD
Bortezomib—PSMA1—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00404	0.0139	CbGpPWpGaD
Bortezomib—PSMD1—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00402	0.0139	CbGpPWpGaD
Bortezomib—CTSG—Degradation of the extracellular matrix—SPP1—nephrolithiasis	0.00401	0.0138	CbGpPWpGaD
Bortezomib—PSMD2—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.004	0.0138	CbGpPWpGaD
Bortezomib—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00396	0.00915	CcSEcCtD
Bortezomib—Gout—Hydrochlorothiazide—nephrolithiasis	0.00393	0.00909	CcSEcCtD
Bortezomib—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00383	0.00886	CcSEcCtD
Bortezomib—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.00376	0.0087	CcSEcCtD
Bortezomib—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00864	CcSEcCtD
Bortezomib—SLC31A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00372	0.0128	CbGpPWpGaD
Bortezomib—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00372	0.00859	CcSEcCtD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00369	0.0127	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00369	0.0127	CbGpPWpGaD
Bortezomib—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00367	0.00849	CcSEcCtD
Bortezomib—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00361	0.00834	CcSEcCtD
Bortezomib—PSMA1—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.0036	0.0124	CbGpPWpGaD
Bortezomib—PSMD1—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00358	0.0124	CbGpPWpGaD
Bortezomib—PSMD2—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00357	0.0123	CbGpPWpGaD
Bortezomib—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00357	0.00824	CcSEcCtD
Bortezomib—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00335	0.00775	CcSEcCtD
Bortezomib—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00767	CcSEcCtD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00329	0.0113	CbGpPWpGaD
Bortezomib—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00755	CcSEcCtD
Bortezomib—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00308	0.00712	CcSEcCtD
Bortezomib—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00306	0.00708	CcSEcCtD
Bortezomib—PSMB2—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00306	0.0106	CbGpPWpGaD
Bortezomib—PSMB1—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00306	0.0106	CbGpPWpGaD
Bortezomib—PSMB5—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00306	0.0106	CbGpPWpGaD
Bortezomib—PSMB8—Amino acid and derivative metabolism—GRHPR—nephrolithiasis	0.00302	0.0104	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00301	0.0104	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00301	0.0104	CbGpPWpGaD
Bortezomib—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00301	0.00695	CcSEcCtD
Bortezomib—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00298	0.00689	CcSEcCtD
Bortezomib—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00682	CcSEcCtD
Bortezomib—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00664	CcSEcCtD
Bortezomib—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00656	CcSEcCtD
Bortezomib—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00281	0.0065	CcSEcCtD
Bortezomib—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00647	CcSEcCtD
Bortezomib—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00647	CcSEcCtD
Bortezomib—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00277	0.00639	CcSEcCtD
Bortezomib—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00634	CcSEcCtD
Bortezomib—PSMB1—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00273	0.00941	CbGpPWpGaD
Bortezomib—PSMB2—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00273	0.00941	CbGpPWpGaD
Bortezomib—PSMB5—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00273	0.00941	CbGpPWpGaD
Bortezomib—PSMB8—Amino acid and derivative metabolism—AGXT—nephrolithiasis	0.00269	0.00928	CbGpPWpGaD
Bortezomib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00268	0.00619	CcSEcCtD
Bortezomib—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00616	CcSEcCtD
Bortezomib—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00616	CcSEcCtD
Bortezomib—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00611	CcSEcCtD
Bortezomib—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00262	0.00606	CcSEcCtD
Bortezomib—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00257	0.00595	CcSEcCtD
Bortezomib—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.00251	0.00579	CcSEcCtD
Bortezomib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00565	CcSEcCtD
Bortezomib—CYP2C8—renal system—nephrolithiasis	0.00244	0.00939	CbGeAlD
Bortezomib—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00243	0.00563	CcSEcCtD
Bortezomib—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00243	0.00563	CcSEcCtD
Bortezomib—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00243	0.00561	CcSEcCtD
Bortezomib—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00557	CcSEcCtD
Bortezomib—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00555	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00555	CcSEcCtD
Bortezomib—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00236	0.00545	CcSEcCtD
Bortezomib—CYP2C8—kidney—nephrolithiasis	0.00236	0.00908	CbGeAlD
Bortezomib—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00235	0.00543	CcSEcCtD
Bortezomib—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00536	CcSEcCtD
Bortezomib—Influenza—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00532	CcSEcCtD
Bortezomib—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00532	CcSEcCtD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00228	0.00787	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00228	0.00787	CbGpPWpGaD
Bortezomib—CYP1A2—renal system—nephrolithiasis	0.00228	0.00879	CbGeAlD
Bortezomib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00226	0.00522	CcSEcCtD
Bortezomib—CYP1A1—renal system—nephrolithiasis	0.00225	0.00867	CbGeAlD
Bortezomib—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00224	0.00519	CcSEcCtD
Bortezomib—CYP1A1—kidney—nephrolithiasis	0.00218	0.00838	CbGeAlD
Bortezomib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00215	0.00498	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00495	CcSEcCtD
Bortezomib—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00213	0.00492	CcSEcCtD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00212	0.00731	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00212	0.00731	CbGpPWpGaD
Bortezomib—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00212	0.0049	CcSEcCtD
Bortezomib—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00486	CcSEcCtD
Bortezomib—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00485	CcSEcCtD
Bortezomib—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00208	0.0048	CcSEcCtD
Bortezomib—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00207	0.00477	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00471	CcSEcCtD
Bortezomib—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00468	CcSEcCtD
Bortezomib—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00202	0.00467	CcSEcCtD
Bortezomib—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00201	0.00465	CcSEcCtD
Bortezomib—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00201	0.00465	CcSEcCtD
Bortezomib—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.002	0.00461	CcSEcCtD
Bortezomib—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.002	0.00461	CcSEcCtD
Bortezomib—PTGS1—renal system—nephrolithiasis	0.00198	0.00762	CbGeAlD
Bortezomib—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00196	0.00453	CcSEcCtD
Bortezomib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00448	CcSEcCtD
Bortezomib—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00445	CcSEcCtD
Bortezomib—PTGS1—kidney—nephrolithiasis	0.00191	0.00736	CbGeAlD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00189	0.00652	CbGpPWpGaD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00189	0.00652	CbGpPWpGaD
Bortezomib—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00188	0.00434	CcSEcCtD
Bortezomib—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00426	CcSEcCtD
Bortezomib—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00424	CcSEcCtD
Bortezomib—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00182	0.0042	CcSEcCtD
Bortezomib—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00178	0.00411	CcSEcCtD
Bortezomib—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00403	CcSEcCtD
Bortezomib—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00172	0.00397	CcSEcCtD
Bortezomib—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00396	CcSEcCtD
Bortezomib—CTSG—Extracellular matrix organization—SPP1—nephrolithiasis	0.00168	0.00579	CbGpPWpGaD
Bortezomib—CYP3A4—renal system—nephrolithiasis	0.00165	0.00636	CbGeAlD
Bortezomib—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00165	0.00381	CcSEcCtD
Bortezomib—CYP2D6—renal system—nephrolithiasis	0.00162	0.00626	CbGeAlD
Bortezomib—Erythema—Hydrochlorothiazide—nephrolithiasis	0.0016	0.00371	CcSEcCtD
Bortezomib—CYP3A4—kidney—nephrolithiasis	0.0016	0.00615	CbGeAlD
Bortezomib—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00158	0.00366	CcSEcCtD
Bortezomib—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00363	CcSEcCtD
Bortezomib—CYP2D6—kidney—nephrolithiasis	0.00157	0.00605	CbGeAlD
Bortezomib—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00155	0.00359	CcSEcCtD
Bortezomib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00357	CcSEcCtD
Bortezomib—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00151	0.0035	CcSEcCtD
Bortezomib—SLC31A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00151	0.00521	CbGpPWpGaD
Bortezomib—Tremor—Hydrochlorothiazide—nephrolithiasis	0.0015	0.00348	CcSEcCtD
Bortezomib—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00149	0.00344	CcSEcCtD
Bortezomib—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00148	0.00343	CcSEcCtD
Bortezomib—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00341	CcSEcCtD
Bortezomib—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00147	0.00339	CcSEcCtD
Bortezomib—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00145	0.00335	CcSEcCtD
Bortezomib—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00144	0.00333	CcSEcCtD
Bortezomib—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00144	0.00333	CcSEcCtD
Bortezomib—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00144	0.00332	CcSEcCtD
Bortezomib—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00142	0.00328	CcSEcCtD
Bortezomib—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00141	0.00326	CcSEcCtD
Bortezomib—Cough—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00324	CcSEcCtD
Bortezomib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00137	0.00316	CcSEcCtD
Bortezomib—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00137	0.00316	CcSEcCtD
Bortezomib—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00137	0.00316	CcSEcCtD
Bortezomib—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00136	0.00315	CcSEcCtD
Bortezomib—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00135	0.00312	CcSEcCtD
Bortezomib—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00132	0.00305	CcSEcCtD
Bortezomib—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00303	CcSEcCtD
Bortezomib—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00303	CcSEcCtD
Bortezomib—PTGS1—Biological oxidations—SLC26A1—nephrolithiasis	0.0013	0.00449	CbGpPWpGaD
Bortezomib—Shock—Hydrochlorothiazide—nephrolithiasis	0.00129	0.00298	CcSEcCtD
Bortezomib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00128	0.00296	CcSEcCtD
Bortezomib—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00128	0.00296	CcSEcCtD
Bortezomib—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00127	0.00293	CcSEcCtD
Bortezomib—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00125	0.00289	CcSEcCtD
Bortezomib—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00122	0.00283	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00119	0.00276	CcSEcCtD
Bortezomib—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00118	0.00274	CcSEcCtD
Bortezomib—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00118	0.00272	CcSEcCtD
Bortezomib—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00117	0.0027	CcSEcCtD
Bortezomib—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00115	0.00267	CcSEcCtD
Bortezomib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00114	0.00263	CcSEcCtD
Bortezomib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00113	0.00261	CcSEcCtD
Bortezomib—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00259	CcSEcCtD
Bortezomib—Pain—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00259	CcSEcCtD
Bortezomib—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00108	0.0025	CcSEcCtD
Bortezomib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00248	CcSEcCtD
Bortezomib—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00241	CcSEcCtD
Bortezomib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00239	CcSEcCtD
Bortezomib—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00104	0.00239	CcSEcCtD
Bortezomib—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.001	0.00345	CbGpPWpGaD
Bortezomib—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000965	0.00223	CcSEcCtD
Bortezomib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00094	0.00217	CcSEcCtD
Bortezomib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000927	0.00214	CcSEcCtD
Bortezomib—CYP1A1—Biological oxidations—SLC26A1—nephrolithiasis	0.000918	0.00316	CbGpPWpGaD
Bortezomib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000896	0.00207	CcSEcCtD
Bortezomib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000866	0.002	CcSEcCtD
Bortezomib—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000842	0.0029	CbGpPWpGaD
Bortezomib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000833	0.00193	CcSEcCtD
Bortezomib—Rash—Hydrochlorothiazide—nephrolithiasis	0.000826	0.00191	CcSEcCtD
Bortezomib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000825	0.00191	CcSEcCtD
Bortezomib—Headache—Hydrochlorothiazide—nephrolithiasis	0.000821	0.0019	CcSEcCtD
Bortezomib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000778	0.0018	CcSEcCtD
Bortezomib—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.000751	0.00259	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—GRHPR—nephrolithiasis	0.000742	0.00256	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—GRHPR—nephrolithiasis	0.000739	0.00255	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—GRHPR—nephrolithiasis	0.000735	0.00253	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ADCY10—nephrolithiasis	0.00073	0.00252	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ADCY10—nephrolithiasis	0.000726	0.0025	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ADCY10—nephrolithiasis	0.000723	0.00249	CbGpPWpGaD
Bortezomib—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000691	0.00238	CbGpPWpGaD
Bortezomib—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000685	0.00236	CbGpPWpGaD
Bortezomib—PSMA1—Disease—SLC26A1—nephrolithiasis	0.000672	0.00231	CbGpPWpGaD
Bortezomib—PSMD1—Disease—SLC26A1—nephrolithiasis	0.000668	0.0023	CbGpPWpGaD
Bortezomib—PSMD2—Disease—SLC26A1—nephrolithiasis	0.000665	0.00229	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AGXT—nephrolithiasis	0.000661	0.00228	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AGXT—nephrolithiasis	0.000658	0.00227	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AGXT—nephrolithiasis	0.000655	0.00226	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—RGS14—nephrolithiasis	0.000621	0.00214	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—RGS14—nephrolithiasis	0.000618	0.00213	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—RGS14—nephrolithiasis	0.000615	0.00212	CbGpPWpGaD
Bortezomib—PSMA1—Disease—ATP6V0A4—nephrolithiasis	0.000599	0.00206	CbGpPWpGaD
Bortezomib—PSMD1—Disease—ATP6V0A4—nephrolithiasis	0.000596	0.00205	CbGpPWpGaD
Bortezomib—PSMD2—Disease—ATP6V0A4—nephrolithiasis	0.000593	0.00204	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000585	0.00202	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—GRHPR—nephrolithiasis	0.000562	0.00194	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—GRHPR—nephrolithiasis	0.000562	0.00194	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—GRHPR—nephrolithiasis	0.000562	0.00194	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—SLC26A1—nephrolithiasis	0.000562	0.00194	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—APRT—nephrolithiasis	0.000562	0.00194	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—APRT—nephrolithiasis	0.00056	0.00193	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—SLC26A1—nephrolithiasis	0.00056	0.00193	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—SLC26A1—nephrolithiasis	0.000557	0.00192	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—APRT—nephrolithiasis	0.000557	0.00192	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—GRHPR—nephrolithiasis	0.000554	0.00191	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ADCY10—nephrolithiasis	0.000553	0.00191	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ADCY10—nephrolithiasis	0.000553	0.00191	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ADCY10—nephrolithiasis	0.000553	0.00191	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ADCY10—nephrolithiasis	0.000545	0.00188	CbGpPWpGaD
Bortezomib—PSMB2—Disease—SLC26A1—nephrolithiasis	0.000509	0.00175	CbGpPWpGaD
Bortezomib—PSMB5—Disease—SLC26A1—nephrolithiasis	0.000509	0.00175	CbGpPWpGaD
Bortezomib—PSMB1—Disease—SLC26A1—nephrolithiasis	0.000509	0.00175	CbGpPWpGaD
Bortezomib—PSMB8—Disease—SLC26A1—nephrolithiasis	0.000502	0.00173	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AGXT—nephrolithiasis	0.000501	0.00173	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AGXT—nephrolithiasis	0.000501	0.00173	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AGXT—nephrolithiasis	0.000501	0.00173	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AGXT—nephrolithiasis	0.000494	0.0017	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—RGS14—nephrolithiasis	0.00047	0.00162	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—RGS14—nephrolithiasis	0.00047	0.00162	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—RGS14—nephrolithiasis	0.00047	0.00162	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—RGS14—nephrolithiasis	0.000464	0.0016	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ATP6V0A4—nephrolithiasis	0.000454	0.00156	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ATP6V0A4—nephrolithiasis	0.000454	0.00156	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ATP6V0A4—nephrolithiasis	0.000454	0.00156	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000452	0.00156	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ATP6V0A4—nephrolithiasis	0.000447	0.00154	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—APRT—nephrolithiasis	0.000426	0.00147	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—APRT—nephrolithiasis	0.000426	0.00147	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—APRT—nephrolithiasis	0.000426	0.00147	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—SLC26A1—nephrolithiasis	0.000426	0.00147	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—SLC26A1—nephrolithiasis	0.000426	0.00147	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—SLC26A1—nephrolithiasis	0.000426	0.00147	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—APRT—nephrolithiasis	0.00042	0.00145	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—SLC26A1—nephrolithiasis	0.00042	0.00145	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—DGKH—nephrolithiasis	0.000419	0.00144	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000419	0.00144	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—DGKH—nephrolithiasis	0.000417	0.00144	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000417	0.00144	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000415	0.00143	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—DGKH—nephrolithiasis	0.000415	0.00143	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AQP1—nephrolithiasis	0.000401	0.00138	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AQP1—nephrolithiasis	0.000399	0.00137	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AQP1—nephrolithiasis	0.000397	0.00137	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—CHRM3—nephrolithiasis	0.000362	0.00125	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—CHRM3—nephrolithiasis	0.000361	0.00124	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—CHRM3—nephrolithiasis	0.000359	0.00124	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—DGKH—nephrolithiasis	0.000318	0.00109	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—DGKH—nephrolithiasis	0.000318	0.00109	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000318	0.00109	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—DGKH—nephrolithiasis	0.000318	0.00109	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000318	0.00109	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000318	0.00109	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000313	0.00108	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—DGKH—nephrolithiasis	0.000313	0.00108	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AQP1—nephrolithiasis	0.000304	0.00105	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AQP1—nephrolithiasis	0.000304	0.00105	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AQP1—nephrolithiasis	0.000304	0.00105	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CHRM3—nephrolithiasis	0.000303	0.00104	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CHRM3—nephrolithiasis	0.000302	0.00104	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CHRM3—nephrolithiasis	0.0003	0.00103	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AQP1—nephrolithiasis	0.000299	0.00103	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GRHPR—nephrolithiasis	0.000294	0.00101	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PTH—nephrolithiasis	0.000277	0.000955	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PTH—nephrolithiasis	0.000276	0.000951	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CHRM3—nephrolithiasis	0.000275	0.000947	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CHRM3—nephrolithiasis	0.000275	0.000947	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CHRM3—nephrolithiasis	0.000275	0.000947	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PTH—nephrolithiasis	0.000275	0.000946	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CHRM3—nephrolithiasis	0.000271	0.000933	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AGXT—nephrolithiasis	0.000262	0.000903	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CHRM3—nephrolithiasis	0.00023	0.000792	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CHRM3—nephrolithiasis	0.00023	0.000792	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CHRM3—nephrolithiasis	0.00023	0.000792	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CHRM3—nephrolithiasis	0.000226	0.00078	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APRT—nephrolithiasis	0.000223	0.000768	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—SLC26A1—nephrolithiasis	0.000223	0.000768	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTH—nephrolithiasis	0.00021	0.000724	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTH—nephrolithiasis	0.00021	0.000724	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTH—nephrolithiasis	0.00021	0.000724	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GRHPR—nephrolithiasis	0.000207	0.000714	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTH—nephrolithiasis	0.000207	0.000714	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GRHPR—nephrolithiasis	0.00019	0.000655	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AGXT—nephrolithiasis	0.000185	0.000636	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.00017	0.000584	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AGXT—nephrolithiasis	0.000169	0.000583	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AQP1—nephrolithiasis	0.000159	0.000547	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SLC26A1—nephrolithiasis	0.000157	0.000541	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APRT—nephrolithiasis	0.000157	0.000541	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000156	0.000537	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.000155	0.000533	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000151	0.000521	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	0.000144	0.000496	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APRT—nephrolithiasis	0.000144	0.000496	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CHRM3—nephrolithiasis	0.000144	0.000495	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—SPP1—nephrolithiasis	0.000139	0.00048	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000139	0.000479	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SPP1—nephrolithiasis	0.000138	0.000477	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SPP1—nephrolithiasis	0.000138	0.000475	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000138	0.000475	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000132	0.000455	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000128	0.000443	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000128	0.000443	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000118	0.000407	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000118	0.000407	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.000118	0.000406	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	0.000117	0.000404	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APRT—nephrolithiasis	0.000117	0.000404	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AQP1—nephrolithiasis	0.000112	0.000386	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SPP1—nephrolithiasis	0.000105	0.000363	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SPP1—nephrolithiasis	0.000105	0.000363	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SPP1—nephrolithiasis	0.000105	0.000363	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SPP1—nephrolithiasis	0.000104	0.000358	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AQP1—nephrolithiasis	0.000103	0.000353	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000102	0.000351	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CHRM3—nephrolithiasis	0.000101	0.000349	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APRT—nephrolithiasis	0.0001	0.000345	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	0.0001	0.000345	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CHRM3—nephrolithiasis	9.27e-05	0.00032	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AQP1—nephrolithiasis	9.15e-05	0.000315	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AGXT—nephrolithiasis	9.09e-05	0.000313	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AQP1—nephrolithiasis	8.42e-05	0.00029	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AQP1—nephrolithiasis	8.35e-05	0.000288	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CHRM3—nephrolithiasis	8.28e-05	0.000285	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	7.73e-05	0.000266	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APRT—nephrolithiasis	7.73e-05	0.000266	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CHRM3—nephrolithiasis	7.61e-05	0.000262	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CHRM3—nephrolithiasis	7.55e-05	0.00026	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AQP1—nephrolithiasis	7.13e-05	0.000246	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CHRM3—nephrolithiasis	6.45e-05	0.000222	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AQP1—nephrolithiasis	5.5e-05	0.00019	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	4.98e-05	0.000172	CbGpPWpGaD
